WASHINGTON, March 31, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration ...
Once again, Vanda Pharmaceuticals is challenging the FDA in court. This time, the company says the agency failed to give its application for Hetlioz in jet lag disorder a proper hearing after the FDA ...
The FDA’s rejection of Vanda Pharmaceuticals’ stomach disease candidate has done little to dampen the enthusiasm of England’s Cycle Pharmaceuticals to acquire the Washington D.C.-based company. On ...
The price trend for Vanda Pharmaceuticals (VNDA) has been bearish lately and the stock has lost 5.8% over the past week. However, the formation of a hammer chart pattern in its last trading session ...
FDA requests, and Vanda agrees to, a brief extension (to December 5, 2025) for the expedited re-review of the partial clinical hold on long-term studies Separately, FDA recently issued labeling ...
Detailed price information for Vanda Pharmaceuticals (VNDA-Q) from The Globe and Mail including charting and trades.
Vanda Pharmaceuticals Inc. stock is down 17% since my July "hold" rating; the FDA approved Fanapt for bipolar I disorder, and stock jumped. The approval of Fanapt for bipolar disorder may not ...
The Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) issued a notice summarizing the grounds for refusing a new drug application (NDA) ...
Update 9:40am: Updates shares, adds company confirmations. Vanda Pharmaceuticals (NASDAQ:VNDA) jumped 22% after Cycle Pharmaceuticals made an unsolicited takeover offer. Cycle is offering to acquire ...
Vanda Pharmaceuticals’ expansion into the booming GLP-1 market has cleared a midphase test. With the trial linking tradipitant to reduced nausea and vomiting in Wegovy patients, the biotech is gearing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results